SCHEDULE 13G/A: BlackRock Amends Passive Stake in Caribou Biosciences
Ownership Disclosure
BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing a 2.0% passive ownership stake in Caribou Biosciences, Inc. as of June 30, 2025.
Summary
- BlackRock, Inc. filed Amendment No. 3 to its Schedule 13G concerning its beneficial ownership in Caribou Biosciences, Inc.
- As of June 30, 2025, BlackRock beneficially owns an aggregate of 1,843,794 shares of Caribou Biosciences' Common Stock.
- This ownership represents 2.0% of the total outstanding class of securities.
- BlackRock holds sole voting power over 1,833,677 shares and sole dispositive power over 1,843,794 shares.
- The filing certifies that the securities were acquired and are held in the ordinary course of business, without the purpose or effect of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: Neutral, as this is a routine regulatory filing disclosing passive ownership and does not contain performance or forward-looking statements from the issuer.
Positives
- NA
Negatives
- NA
Risks
- NA
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's passive stake, confirming BlackRock's continued holding of a minor percentage of shares.
- Management: Confirms BlackRock's passive investment stance, indicating no intent to influence control over the issuer.
Key Dates
| Date | Description |
|---|---|
| 01/21/2025 | Date of execution of the Power of Attorney by BlackRock, Inc. |
| 06/30/2025 | Date of event which requires filing of this statement (reporting period end date for beneficial ownership calculation). |
| 07/16/2025 | Date of filing of the Schedule 13G Amendment No. 3. |
Keywords
BlackRock, Caribou Biosciences, Schedule 13G, Ownership Disclosure, Institutional Investor, Common Stock, Biotechnology, CRISPR
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.